Clinical Trials Logo
  1. Home
  2. Other
  3. NCT00746967

An Open-Label, Extension Study Evaluating the Safety, Toleration, and Efficacy of Sildenafil in Women With Sexual Arousal Disorder

Sexual Dysfunctions, Psychological Clinical Trial

Official title:
An Open-Label, Multi-Center Extension Study To Evaluate The Safety, Toleration And Sustained Efficacy Of Oral Sildenafil Administered To Women Who Have Been Diagnosed With Female Sexual Arousal Disorder

Clinical Trial Summary

The purpose of this study is to evaluate the safety and toleration of oral sildenafil administered as required by women with Female Sexual Arousal Disorder (FSAD) who successfully complete one of the following Pfizer-sponsored, 12-week, double-blinded clinical trials: A1481082 or A1481123. Addition of this 52-week open-label extension will increase the total duration of sildenafil exposure to 64 weeks. Sustained efficacy will also be evaluated after 3 and 6 months of open-label therapy.

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Clinical Trial Details
NCT number NCT00746967
Study type Interventional
Source Pfizer
Contact
Status Completed
Phase Phase 2
Start date January 2003
Completion date February 2004
View Details
See also
  Status Clinical Trial Phase
Completed NCT00996372 - Flibanserin for the Treatment of Hypoactive Sexual Desire Disorder in Postmenopausal Women Phase 3
Completed NCT00996164 - Fixed 100 mg Every Evening of Flibanserin vs Placebo in Premenopausal Women With Hypoactive Sexual Desire Disorder Phase 3
Recruiting NCT05777031 - Safety and Efficacy of Collagenase Clostridium Histolyticum After Prior Intralesional PRP for Peyronie's Disease Phase 4
Completed NCT01188720 - Sexual Health on Antidepressants Through Physical Exercise N/A
Completed NCT00175539 - Group Psychoeducational Treatment for Women With Sexual Arousal Difficulties N/A
Completed NCT04792177 - Internet-based Emotion Regulation Intervention for Sexual Health N/A
Completed NCT02381912 - Sexual Function in Patients Suspected of Non-muscle Invasive Bladder Cancer N/A
Completed NCT03241524 - Consistency of Questionnaires to Evaluating Sexual Functions in Young Healthy Women N/A
Completed NCT00491829 - Flibanserin Versus Placebo in Premenopausal Women With HSDD Phase 3
Completed NCT00034021 - Ginkgo Biloba: Antidepressant-Induced Sexual Dysfunction Phase 2
Recruiting NCT05489133 - Early Psychological Intervention After Rape N/A
Completed NCT03775239 - Mindfulness as Treatment of Sexological Problems N/A
Completed NCT01654458 - A Randomized Controlled Trial of an Online Support Group for Sexual Distress Due to Gynecologic Cancer N/A
Completed NCT01188603 - Pharmacokinetics of Flibanserin in Postmenopausal Women With Hypoactive Sexual Desire Disorder (HSDD) Phase 1
Completed NCT01771237 - HIV Prevention Among Vulnerable Male Youth N/A
Completed NCT00360243 - 6-mo. Min Eff Dose of Flibanserin: 25 v 50 mg Bid v 50 mg hs v Pbo in Younger Women in NA Phase 3
Completed NCT00360529 - 24-Week Placebo-Controlled Trial of Flibanserin Once Daily in Premenopausal Women With Hypoactive Sexual Desire Disorder Phase 3
Completed NCT00360555 - A Twenty Four Uptitration Trial of Flibanserin Versus Placebo in Premenopausal Women With Hypoactive Sexual Desire Disorder Phase 3
Recruiting NCT05456919 - Quality of Sexual Function in BRCA Mutated Women
Terminated NCT01040208 - 12 Week Safety Trial of Flibanserin in Depressed Women Taking a Selective Serotonin Reuptake Inhibitor or Norepinephrine Serotonin Reuptake Inhibitor With Decreased Sexual Desire and Distress Phase 3